Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;59(4):2432-4.
doi: 10.1128/AAC.04568-14. Epub 2015 Jan 20.

Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012

D J Farrell  1 , R E Mendes  1 , R N Jones  2
Affiliations

Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012

D J Farrell et al. Antimicrob Agents Chemother. 2015 Apr.

Abstract

Solithromycin, a next-generation macrolide and novel fluoroketolide, was tested against a 2012 collection of serotyped U.S. macrolide-resistant Streptococcus pneumoniae isolates associated with community-acquired bacterial pneumonia (CABP). Against all 272 isolates, solithromycin demonstrated high potency (MIC50/90, 0.06/0.25 μg/ml), and it inhibited all strains at MICs of ≤0.5 μg/ml, including the two most prevalent macrolide-resistant serotypes (19A and 35B). These data support the continued clinical development of solithromycin for the treatment of multidrug-resistant CABP.

PubMed Disclaimer

References

    1. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A. 2006. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368:1495–1502. doi:10.1016/S0140-6736(06)69637-2. - DOI - PubMed
    1. Jacobs MR, Good CE, Bajaksouzian S, Windau AR. 2008. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis 47:1388–1395. doi:10.1086/592972. - DOI - PubMed
    1. Farrell DJ, Klugman KP, Pichichero M. 2007. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 26:123–128. doi:10.1097/01.inf.0000253059.84602.c3. - DOI - PubMed
    1. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. 2013. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999–2011. Emerg Infect Dis 19:1074–1083. doi:10.3201/eid1907.121830. - DOI - PMC - PubMed
    1. Farrell DJ, Sader HS, Castanheira M, Biedenbach DJ, Rhomberg PR, Jones RN. 2010. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. Int J Antimicrob Agents 35:537–543. doi:10.1016/j.ijantimicag.2010.01.026. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources